Connolly et al. showed that the early changes in tumor maximum standardized uptake value corrected for lean body mass (SULmax) of PET/CT parameter predict pathologic complete response to neoadjuvant TP in stage II or III of patients with estrogen receptor-negative and HER2-positive breast cancer [23]. This evidence concerns the gene ERBB2 and breast cancer.